ProfileGDS5678 / 1436739_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 68% 71% 81% 74% 68% 62% 71% 85% 77% 66% 71% 76% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3316870
GSM967853U87-EV human glioblastoma xenograft - Control 24.1447768
GSM967854U87-EV human glioblastoma xenograft - Control 34.5101271
GSM967855U87-EV human glioblastoma xenograft - Control 45.9170781
GSM967856U87-EV human glioblastoma xenograft - Control 54.8226374
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1657668
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.772562
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.484571
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3926485
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2548577
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0036266
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4951571
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1180976
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9626375